Form 4: Amicus Therapeutics Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
Ellen Rosenberg, Chief Legal Officer of Amicus Therapeutics, reports acquisition and disposal of common stock.
Summary
- Ellen Rosenberg, the Chief Legal Officer of Amicus Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On February 11, 2025, Rosenberg acquired 64,800 shares of common stock at $0, and disposed of 28,584 shares at $9.57.
- Following these transactions, Rosenberg directly owns 507,710 shares of common stock and indirectly owns 15,000 shares through a spouse.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the actions of company executives.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
- It may influence investor sentiment depending on the size and nature of the transactions.
Key Dates
| Date | Description |
|---|---|
| 02/11/2025 | Date of stock acquisition and disposal. |
| 02/13/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Amicus Therapeutics, Rosenberg, FOLD
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.